Shares of Cipher Pharmaceuticals Inc. (TSE:CPH – Get Free Report) (NASDAQ:CPHR) passed below its 50 day moving average during trading on Thursday . The stock has a 50 day moving average of C$17.85 and traded as low as C$16.56. Cipher Pharmaceuticals shares last traded at C$16.75, with a volume of 14,637 shares trading hands.
Analyst Upgrades and Downgrades
Separately, Canaccord Genuity Group set a C$17.00 price target on Cipher Pharmaceuticals and gave the stock a “hold” rating in a report on Tuesday, May 12th. One analyst has rated the stock with a Hold rating, Based on data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average price target of C$17.00.
View Our Latest Stock Report on CPH
Cipher Pharmaceuticals Stock Up 0.5%
Cipher Pharmaceuticals (TSE:CPH – Get Free Report) (NASDAQ:CPHR) last announced its quarterly earnings data on Thursday, May 7th. The company reported C$0.33 EPS for the quarter. Cipher Pharmaceuticals had a net margin of 60.82% and a return on equity of 25.69%. The firm had revenue of C$17.39 million during the quarter. As a group, equities research analysts forecast that Cipher Pharmaceuticals Inc. will post 1.2907348 earnings per share for the current year.
About Cipher Pharmaceuticals
Cipher Pharmaceuticals (TSX: CPH) (OTCQX: CPHRF) is a specialty pharmaceutical company with a robust and diversified portfolio of commercial and early to late-stage products, mainly in dermatology. Cipher acquires products that fulfill unmet medical needs, manages the required clinical development and regulatory approval process, and currently markets those products in Canada, the U.S., and South America.
Further Reading
- Five stocks we like better than Cipher Pharmaceuticals
- Samsara Just Answered The AI Question—Is Wall Street Ready To Listen?
- IREN’s 800MW Bet Flips the AI Power Switch
- CrowdStrike Earnings Beat Sparks Selloff—Buy the Dip?
- Tesla’s EV Rebound Leaves Rivian and Lucid Facing a Tougher Investor Test
Receive News & Ratings for Cipher Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cipher Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
